Liu Yukun, Fan Ziwen, Li Shaowu, Liu Xing, Jiang Tao, Wang Yinyan, Wang Lei
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Ann Transl Med. 2022 Jun;10(11):627. doi: 10.21037/atm-21-3998.
Although the influence of molecular biomarkers on the biological behavior of tumor cells has been investigated, their quantitative influence on the velocity of tumor growth remains unclear. This study aimed to identify the molecular biomarkers associated with tumor growth rates in World Health Organization (WHO) grade II gliomas, or low-grade gliomas (LGGs).
Preoperative magnetic resonance imaging (MRI) data of patients with LGGs were retrospectively reviewed. Patients with at least 2 preoperative MRIs taken more than 90 days apart were enrolled. Patients with isocitrate dehydrogenase () wild-type tumors or with no recorded status were excluded. A linear mixed-effects model was used to assess the velocity of tumor diameter expansion. The effect of biomarker expression on tumor growth rate was assessed using a multivariate linear mixed-effects regression model.
Data from 56 patients were used in our study. The overall velocity of diameter expansion (VDE) for LGGs was 2.1 mm/year. Higher expression level of mutant p53 were significantly associated with a higher tumor growth rate (+1.9 mm/year, P<0.01), while higher expression level of alpha-thalassemia/mental retardation syndrome X-linked protein (ATRX) were significantly associated with a lower tumor growth rate (-1.3 mm/year, P<0.01). Tumors with O6-methylguanine-DNA methyltransferase () promoter methylation were found to grow significantly more slowly than those with no methylation (-3.1 mm/year, P<0.01). The telomerase reverse transcriptase () promoter type and expressions levels of Ki-67 and epidermal growth factor receptor (EGFR) showed no significant independent impact on tumor growth rates.
The status of biomarkers is significantly associated with the tumor growth rate in LGGs.
尽管已经研究了分子生物标志物对肿瘤细胞生物学行为的影响，但其对肿瘤生长速度的定量影响仍不清楚。本研究旨在确定与世界卫生组织（WHO）二级胶质瘤或低级别胶质瘤（LGG）肿瘤生长速率相关的分子生物标志物。
回顾性分析LGG患者的术前磁共振成像（MRI）数据。纳入至少有2次间隔超过90天的术前MRI检查的患者。排除异柠檬酸脱氢酶（）野生型肿瘤患者或未记录状态的患者。使用线性混合效应模型评估肿瘤直径扩大的速度。使用多变量线性混合效应回归模型评估生物标志物表达对肿瘤生长速率的影响。
本研究使用了56例患者的数据。LGG的直径总体扩大速度（VDE）为2.1毫米/年。突变型p53的较高表达水平与较高的肿瘤生长速率显著相关（+1.9毫米/年，P<0.01），而α地中海贫血/智力发育迟缓综合征X连锁蛋白（ATRX）的较高表达水平与较低的肿瘤生长速率显著相关（-1.3毫米/年，P<0.01）。发现具有O6-甲基鸟嘌呤-DNA甲基转移酶（）启动子甲基化的肿瘤生长明显比未甲基化的肿瘤慢（-3.1毫米/年，P<0.01）。端粒酶逆转录酶（）启动子类型以及Ki-67和表皮生长因子受体（EGFR）的表达水平对肿瘤生长速率没有显著的独立影响。
生物标志物状态与LGG的肿瘤生长速率显著相关。
